^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | SCH772984 (ERK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vivo antitumor efficacy of SCH772984 was evaluated in BRAF- or KRAS-mutant xenograft models established from human melanoma or pancreatic carcinoma cell lines.In vivo antitumor efficacy of SCH772984 was evaluated in BRAF- or KRAS-mutant xenograft models established from human melanoma or pancreatic carcinoma cell lines. Treatment of BRAF-mutant LOX melanoma xenografts with SCH772984 (50 mg/kg twice daily) led to 98% tumor regression
Excerpt:
In vivo antitumor efficacy of SCH772984 was evaluated in BRAF- or KRAS-mutant xenograft models established from human melanoma or pancreatic carcinoma cell lines.In vivo antitumor efficacy of SCH772984 was evaluated in BRAF- or KRAS-mutant xenograft models established from human melanoma or pancreatic carcinoma cell lines. Treatment of BRAF-mutant LOX melanoma xenografts with SCH772984 (50 mg/kg twice daily) led to 98% tumor regression.
DOI:
10.1158/2159-8290.CD-13-0070
